Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis.

Published

Journal Article

OBJECTIVE: To evaluate the effects of long-term etanercept treatment, with or without methotrexate, on growth in children with selected categories of juvenile idiopathic arthritis (JIA). METHODS: We conducted a 3-year, open-label, nonrandomized registry of 594 patients with polyarticular or systemic JIA treated with etanercept only, etanercept plus methotrexate, or methotrexate only. Height, weight, and body mass index (BMI) were assessed at baseline and at years 1, 2, and 3, using percentiles derived from US Centers for Disease Control and Prevention standardized growth charts. RESULTS: Statistically significant increases in the mean height percentiles from baseline were observed in etanercept-treated patients at year 3 (4.8 percentile points) and in patients treated with etanercept plus methotrexate at years 1, 2, and 3 (2.4, 3.3, and 5.6 percentile points, respectively). Statistically significant increases from baseline in the mean weight percentiles were observed at years 1, 2, and 3 in both the etanercept group (7.4, 10.0, and 13.0 percentile points) and the etanercept-plus-methotrexate group (2.9, 6.9, and 8.4 percentile points, respectively). Statistically significant increases from baseline in the mean BMI percentiles were observed in both the etanercept group (range 9.6-13.8 percentile points) and the etanercept-plus-methotrexate group (range 2.1-5.2 percentile points). The mean height, weight, and BMI percentiles did not change significantly in patients in the methotrexate-only group. CONCLUSION: Etanercept treatment, with or without methotrexate, may contribute to the restoration of normal growth in children with JIA.

Full Text

Duke Authors

Cited Authors

  • Giannini, EH; Ilowite, NT; Lovell, DJ; Wallace, CA; Rabinovich, CE; Reiff, A; Higgins, G; Gottlieb, B; Chon, Y; Zhang, N; Baumgartner, SW

Published Date

  • November 2010

Published In

Volume / Issue

  • 62 / 11

Start / End Page

  • 3259 - 3264

PubMed ID

  • 20669280

Pubmed Central ID

  • 20669280

Electronic International Standard Serial Number (EISSN)

  • 1529-0131

International Standard Serial Number (ISSN)

  • 0004-3591

Digital Object Identifier (DOI)

  • 10.1002/art.27682

Language

  • eng